Presentation is loading. Please wait.

Presentation is loading. Please wait.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Published byJocelin Lane Modified over 5 years ago

Similar presentations

Presentation on theme: "Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology."— Presentation transcript:

1 Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) For permissions, please article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ( Eur Heart J, Volume 39, Issue 26, 19 May 2018, Pages 2448–2456, The content of this slide may be subject to copyright: please see the slide notes for details.

2 Take home figure Upper left panel: schematic representation of heterogeneous vessel healing and atherosclerotic changes within ... Take home figure Upper left panel: schematic representation of heterogeneous vessel healing and atherosclerotic changes within the neointima at follow-up in stents with polymeric carrier. Upper right panel: Whisker plot summarizing the distribution of strut coverage of BP-EES and DP-ZES at post-procedure, 3 months and 18 months. No differences were observed between stent types at all time points. No differences were also noted in the maximal length of uncovered struts at 3 months, the 3-month co-primary endpoint of the study not shown here. Bottom panel: bar plot summarizing the proportion of patients with frames of neoatherosclerosis (left), the 18-month co-primary endpoint of the study, and components of neoatherosclerosis (right) at 18 months. No differences were observed between stent types at all time points. *Proportion of embedded struts was considered a surrogate of strut coverage at post-implant. BP-EES, biodegradable-polymer everolimus-eluting stent; DP-ZES, durable-polymer zotarolimus-eluting stent; PCI, percutaneous coronary intervention; TCFA, thin-cap fibroatheroma. Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) For permissions, please article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ( Eur Heart J, Volume 39, Issue 26, 19 May 2018, Pages 2448–2456, The content of this slide may be subject to copyright: please see the slide notes for details.

Download ppt "Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology."

Similar presentations

Figure 1 Rates of complications and mortality during index admission for atrial fibrillation ablation for the overall ... Figure 1 Rates of complications.

Figure 1 Rates of complications and mortality during index admission for atrial fibrillation ablation for the overall ... Figure 1 Rates of complications.
Figure 1 Study flow diagram and definition of clinical response

Figure 1 Study flow diagram and definition of clinical response
Unless provided in the caption above, the following copyright applies to the content of this slide: © 2019 European Society of Cardiology and British Pharmacological.

Unless provided in the caption above, the following copyright applies to the content of this slide: © 2019 European Society of Cardiology and British Pharmacological.
Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.
Figure 1 Data-selection process

Figure 1 Data-selection process
Figure 1 Flow diagram detailing the systematic review process.

Figure 1 Flow diagram detailing the systematic review process.
Figure 1 Schematic representation of the experimental design.

Figure 1 Schematic representation of the experimental design.
Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.
Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.
Figure 1 Unadjusted Kaplan–Meier curves for all-cause mortality in the transcatheter mitral valve repair and ... Figure 1 Unadjusted Kaplan–Meier curves.

Figure 1 Unadjusted Kaplan–Meier curves for all-cause mortality in the transcatheter mitral valve repair and ... Figure 1 Unadjusted Kaplan–Meier curves.
Figure 1 Mechanism of mortality benefit associated with radial access

Figure 1 Mechanism of mortality benefit associated with radial access
Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.
Figure 1 Number of percutaneous coronary interventions (PCI) in mainland China, 2017 (total 753 142). Data from China ... Figure 1 Number of percutaneous.

Figure 1 Number of percutaneous coronary interventions (PCI) in mainland China, 2017 (total 753 142). Data from China ... Figure 1 Number of percutaneous.
Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.
Figure 1 The Kaplan–Meier curves of time to death post first hospitalization. hosp, hospitalization. Unless provided in the caption above, the following.

Figure 1 The Kaplan–Meier curves of time to death post first hospitalization. hosp, hospitalization. Unless provided in the caption above, the following.
Figure 1 Sources of uncertainty introduced in each stage of the standard modelling approach for estimating ... Figure 1 Sources of uncertainty introduced.

Figure 1 Sources of uncertainty introduced in each stage of the standard modelling approach for estimating ... Figure 1 Sources of uncertainty introduced.
AHA: American Heart Association; ALT: ...

AHA: American Heart Association; ALT: ...
Figure 1. Serum ceftazidime concentrations following intravenous administration. Unless provided in the caption above, the following copyright applies.

Figure 1. Serum ceftazidime concentrations following intravenous administration. Unless provided in the caption above, the following copyright applies.
Figure 1 A dot plot illustrating the correlation between the yearly absolute risk difference for both MACE and major ... Figure 1 A dot plot illustrating.

Figure 1 A dot plot illustrating the correlation between the yearly absolute risk difference for both MACE and major ... Figure 1 A dot plot illustrating.
Figure 1 Comparison of MITRA-FR and COAPT trial outcomes

Figure 1 Comparison of MITRA-FR and COAPT trial outcomes

Similar presentations

Ads by Google